Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jason Keith Boyd"'
Autor:
D. Oubre, R. Brian Mitchell, J. Orsini, Edgardo S. Santos, Patricia Rich, Scott Boniol, Warren Brenner, Jonathan Goldberg, Waseemullah Khan, Suman Sinha, Savita Bidyasar, Eric Scott Schaefer, Emily K. Pauli, Paul R. Walker, Kan Huang, Andrea Veatch, Linda Traylor, Maria Quejada, Wallace Akerley, Mitchell Haut, Mazen Khalil, Bassam Ghabach, Ray D. Page, Hafez Halawani, Jason Keith Boyd, J. Dubay
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
PurposeImmune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3604c791c5637fc3d7b0dbb8a428d9a
https://doi.org/10.1136/jitc-2021-002989
https://doi.org/10.1136/jitc-2021-002989
Autor:
Wallace Akerley, Ray D. Page, R. Brian Mitchell, Kan Huang, Mitchell Haut, Jason Keith Boyd, J. Dubay, Nagaprasad Nagajothi, Savita Bidyasar, J. Orsini, Mazen Khalil, Eric Scott Schaefer
Publikováno v:
Cancer Research. 81:662-662
Motivation. A blood-based proteomic host immune classifier (HIC) that identifies a patient's disease state as Hot or Cold can aid prognostication and help guide treatment decisions in non-small cell lung cancer (NSCLC). The HIC Hot label is associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::687c260de6c5bd822951b4f92782d22d
https://doi.org/10.1158/1538-7445.am2021-662
https://doi.org/10.1158/1538-7445.am2021-662
Autor:
D. Oubre, Jiahuai Tan, Nadeem Ikhlaque, Hafez Halawani, Wallace Akerley, Jason Keith Boyd, J. Dubay, Emily K. Pauli, Scott Boniol, Paul R. Walker, Nagaprasad Nagajothi, Ray D. Page, Patricia Rich, Mazen Khalil, R. Brian Mitchell, Insight Investigators, Eric Scott Schaefer, J. Orsini, Edgardo S. Santos, Suman Sinha
Publikováno v:
Journal of Clinical Oncology. 38:9545-9545
9545 Background: Immune checkpoint inhibition (ICI) has improved outcomes for many treatment-naïve advanced non-small cell lung cancer (NSCLC) patients. However, better biomarkers are needed to predict patient response and guide treatment decisions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d70a2d3db2e5d211b5a010dd9606933
https://doi.org/10.1200/jco.2020.38.15_suppl.9545
https://doi.org/10.1200/jco.2020.38.15_suppl.9545
Autor:
Antoni Ribas, Dmitri Pavlov, Laura Q.M. Chow, Craig Davis, Michele Gorczyca, Georgina V. Long, Aron Thall, Jason Keith Boyd
Publikováno v:
Journal of Clinical Oncology. 34:TPS3106-TPS3106
TPS3106Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Additionally, 4-1BB agonists have been...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3993002542d864315f17900e411822a
https://doi.org/10.1200/jco.2016.34.15_suppl.tps3106
https://doi.org/10.1200/jco.2016.34.15_suppl.tps3106